Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005093 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
A Phase 3 study of Lung Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Study locations
NCT00005093: Completed Phase 3 study of Lung Cancer, sponsored by Pfizer.
NCT00005093 is a Phase 3 study of Lung Cancer that has completed, run by Pfizer. The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005093, a Phase 3 study of Lung Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether gemcitabine plus CI-994 is more effective than gemcitabine alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without CI-994 in treating patients who have advanced non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG gemcitabine hydrochloride
- DRUG tacedinaline
Study Locations (16)
British Columbia
- British Columbia Cancer Agency - Fraser Valley Cancer Centre - Surrey
- BC Cancer Agency - Vancouver
- British Columbia Cancer Agency - Vancouver Island Cancer Centre - Victoria
Ontario
- Ottawa Regional Cancer Center - General Division - Ottawa
- Mount Sinai Hospital - Toronto - Toronto
- Princess Margaret Hospital - Toronto
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Barbara Ann Karmanos Cancer Institute - Detroit
California
- Cedars-Sinai Comprehensive Cancer Center - Los Angeles
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Massachusetts
- New England Medical Center Hospital - Boston
North Carolina
- Raleigh Hematology/Oncology Associates - Wake Practice - Raleigh
Ohio
- Arthur G. James Cancer Hospital - Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2001-05 |
| Phase | Phase 3 |
What the finished NCT00005093 record still lists
NCT00005093 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00005093 lists 16 locations in 11 states (British Columbia, Ontario, Michigan).
Frequently Asked Questions
What is clinical trial NCT00005093 about?
NCT00005093 is a clinical study titled "Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether gemcitabine plus CI-994 is more effective than gemcitabine alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the eff...
What is the current status of trial NCT00005093?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-12. Estimated completion is 2001-05.
What conditions does trial NCT00005093 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00005093?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), tacedinaline (DRUG).
Who is sponsoring clinical trial NCT00005093?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005093 being conducted?
This trial has 16 study locations across California, Florida, Massachusetts, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia